Search Results

Nuclea Energy to Acquire Moltex Advanced Nuclear Technology Portfolio

Moltex Energy announced on August 13 that Nuclea Energy Inc. has signed a definitive agreement to acquire its advanced nuclear technology portfolio. The transaction was concluded following a competitive bidding process, with the relevant technologies and company assets having attracted interest from multiple parties earlier. The proposed technology platform, developed over more than a decade, encompasses the Waste-to-Stable Salt (WATSS) spent fuel recycling process, the Stable Salt Reactor – Wasteburner (SSR-W), and FLEX reactor technology. The portfolio includes 80 granted patents across 9 patent families, as well as 9 pending patents related to the WATSS recycling process...

2026-08-14

Nuclea to Explore Building Nuclear Test Reactor in Utah to Advance Morpheus Microreactor Deployment

On August 5, Mangoceuticals announced that Nuclea Energy USA Inc., a wholly owned subsidiary of its merger partner, has signed a memorandum of understanding with the Utah Office of Energy Development to explore siting a nuclear test reactor at the Utah St. Rafael Energy Laboratory to advance the deployment of the Morpheus microreactor. Under the MOU, Nuclea USA and the Utah Office of Energy Development will collaborate on test reactor siting and support related communications and coordination with the U.S. Department of Energy and the U.S. Nuclear Regulatory Commission. The parties will also evaluate pathways for future deployment of Nuclea's technology in Utah. The collaboration is seen as a step in Nuclea's micro modular react...

2026-08-06

Mangoceuticals to Merge with Nuclea to Advance Morpheus Microreactor to Market

Mangoceuticals announced on July 30 that it has signed a definitive business combination agreement with advanced nuclear technology company Nuclea Energy Inc., aiming to bring the latter's Morpheus microreactor to the public capital markets. Nuclea was founded in August 2023 and is headquartered in Mississauga, Ontario, Canada, focusing on the development of lead-cooled, factory-fabricated micro-modular reactors. Under the agreement, a newly formed subsidiary of Mangoceuticals will merge with Nuclea, and the combined company will operate as an indirect wholly owned subsidiary of Mangoceuticals. Upon completion of the transaction, holders of Nuclea common shares will receive...

2026-07-31